Clik here to view.
Larry Andrews steps down as Cipher Pharma head
Larry Andrews will be stepping down from his position as president and CEO of Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND). Larry Andrews To ensure a smooth transition of responsibilities, Mr. Andrews...
View ArticleClik here to view.
Cipher gets sales milestone for Lipofen
Cipher Pharmaceuticals‘ (TSX:DND) Lipofen fenofibrate product reached a cumulative sales milestone, triggering a $1 million (U.S.) milestone payment from Kowa Pharmaceuticals America, Cipher’s U.S....
View ArticleClik here to view.
Cipher gets U.S. patent for tramadol
The U.S. Patent and Trademark Office has issued a patent notice of allowance for Cipher Pharmaceuticals’ (TSX:DND) CIP-Tramadol ER, an extended-release product for the treatment of moderate to...
View ArticleClik here to view.
Cipher completes CIP-Isotretinoin enrolment
Cipher Pharmaceuticals (TSX:DND) has completed patient enrolment in a Phase 3 safety study of its CIP-Isotretinoin treatment of severe, nodular acne. A total of 931 patients were enrolled in the trial,...
View ArticleClik here to view.
Vertical Pharma to distribute Cipher’s tramadol in U.S.
Cipher Pharmaceuticals (TSX:DND) has entered into a distribution and supply agreement with Vertical Pharmaceuticals to market Cipher’s CIP-TRAMADOL ER in the U.S. for the treatment of moderate to...
View ArticleClik here to view.
Cipher signs up Canadian distributor for Tramadol
Cipher Pharmaceuticals (TSX:DND) has entered into a distribution and supply agreement with Medical Futures, a closely held Canadian pharmaceutical company, for the marketing of Durela in Canada. Durela...
View ArticleClik here to view.
Cipher readies regulatory filings for acne product
Cipher Pharmaceuticals (TSX:DND) is on track to file Health Canada and FDA submissions this quarter for its high-potential acne product, CIP-Isotretinoin, which is expected to trigger a $1 million...
View Article